Deep Genomics logo

Deep Genomics

Emerging

Deep Genomics uses AI to discover and design RNA-based therapies for genetic diseases; its AI Workbench platform decodes RNA biology at scale; raised over $180M in funding including a $40M Series C extension in 2022;

Best for: AI-Powered RNA Therapeutics Drug DiscoveryEmerging, rapid growth
36
AI Score
Grade D
AI Visibility Score (Beta)
Life Sciences & BioTechAI-Powered RNA Therapeutics Drug DiscoveryWebsiteUpdated October 2026

Company Overview

About Deep Genomics

Deep Genomics is a biopharmaceutical company founded in 2015 by Brendan Frey and headquartered in Toronto, Ontario, Canada. The company applies artificial intelligence to the challenge of RNA biology — developing a proprietary AI Workbench platform that can predict how genetic variants affect RNA splicing, processing, and gene expression. This computational capability allows Deep Genomics to identify disease-causing mutations that alter RNA function and to design antisense oligonucleotide (ASO) and other RNA-based therapies that correct those molecular defects — a process that traditionally requires years of manual biological experimentation.

Business Model & Competitive Advantage

Deep Genomics' approach is differentiated by the depth of its AI training: the company has generated proprietary biological datasets measuring the functional effects of millions of genetic variants on RNA biology, creating training data that enables its models to make highly accurate predictions about the molecular consequences of disease-associated mutations. This AI-biology flywheel — where experimental data trains better AI models, which design better experiments — allows Deep Genomics to advance drug programs faster and with greater confidence than traditional RNA therapeutics approaches. The company has raised over $180M in total funding, including investments from GV (Google Ventures), 8VC, and others, as well as a 2022 partnership with Alphabet.

Competitive Landscape 2025–2026

Deep Genomics has multiple preclinical programs targeting rare genetic diseases including Wilson disease and Batten disease, conditions caused by specific genetic mutations that disrupt RNA processing. The company operates at the intersection of AI and RNA therapeutics — a convergence that has attracted significant capital given the clinical validation of RNA medicines following the success of COVID-19 mRNA vaccines and approved ASO drugs for conditions including spinal muscular atrophy (SMA).

Founded
2015
Headquarters
Toronto, Ontario
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Deep Genomics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

36
→ Stable

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Tempus logo

Tempus

Life Sciences & BioTech
HealthtechB2bAi PoweredAnalyticsPlatformPublicSaasTechnologyNorth America

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o

Emulate logo

Emulate

Life Sciences & BioTech
HealthtechB2bEnterpriseAi PoweredHardwarePlatformStartupScaleupGlobalNorth America

Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Karius logo

Karius

Life Sciences & BioTech
HealthtechAi PoweredB2bEnterpriseNorth AmericaTechnologyAnalytics

Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens

ConcertAI logo

ConcertAI

Life Sciences & BioTech
HealthtechAi PoweredAnalyticsB2bSaasEnterpriseData WarehousePlatformUnicorn

ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult

DNAnexus logo

DNAnexus

Life Sciences & BioTech
B2bSaasHealthtechCloud NativeAnalyticsEnterprisePlatformGlobalAi PoweredInfrastructure

DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a

Compare Deep Genomics with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Deep Genomics

Claim This Profile

Are you from Deep Genomics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Deep Genomics Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Deep Genomics vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →